Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China ...Middle East

SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...

Hence then, the article about innovent and hutchmed jointly announce that the frusica 2 phase 2 3 study of sintilimab and fruquintinib combination has met its primary endpoint in advanced renal cell carcinoma in china was published today ( Wednesday 19/03/2025 - 03:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China )

Also on site :

• My Daughter’s Friend Has a Crush on My Husband. It’s Making Us Both Deeply Uncomfortable.
• Maga’s biggest fear is coming true and Trump won’t survive it
• Governor Hochul: Annual statewide donation drive is complete